pentobarbital will minimize the level or influence of nicardipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.

Stay clear of; coadministration with CYP3A inducers may perhaps result in lessened plasma concentrations of elvitegravir and/or a concomitantly administered protease inhibitor and produce loss of therapeutic result also to feasible resistance

Comment: Barbiturates may maximize adverse outcomes, together with respiratory depression, made by poisonous doses of TCAs. With therapeutic doses of TCAs, barbiturates raise metabolism and decrease blood concentrations of TCAs.

pentobarbital will decrease the extent or outcome of disopyramide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Not known.

Parenteral alternatives of barbiturates are very alkaline; extreme care ought to be taken to stay away from perivascular extravasation or intra-arterial injection; extravascular injection may possibly lead to community tissue injury with subsequent necrosis; effects of intra-arterial injection may perhaps vary from transient soreness to gangrene with the limb; any complaint of discomfort during the limb warrants stopping the injection

pentobarbital will reduce the extent or result of clozapine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

CYP3A4 inducers might improve the formation from the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely watch people having ifosfamide with CYP3A4 inducers for toxicities and take into account dose adjustment.

Barbiturates might cause fetal problems when administered to some pregnant girl; retrospective, circumstance-managed experiments have prompt a relationship between maternal usage of barbiturates and a better-than-envisioned incidence of fetal abnormalities

pentobarbital will lower the website extent or outcome of diazepam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Robust or moderate CYP3A4 inducers may well improve amount of diazepam elimination; consequently, efficacy of diazepam may very well be reduced.

pentobarbital will decrease the level or effect of paclitaxel protein certain by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.

Coadministration of zuranolone with other CNS depressants could increase impairment of psychomotor performance or CNS depressant results. If unavoidable, think about dose reduction. .

pentobarbital will decrease the extent or outcome of elagolix by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

pentobarbital will minimize the extent or impact of cevimeline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Not known.

Contraindicated (1)pentobarbital will lower the level or impact of cariprazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is answerable for the formation and elimination of cariprazine's active metabolites.